CN102844664A - 对alk抑制剂具有先抗性或后抗性癌症的识别，判断和治疗 - Google Patents

对alk抑制剂具有先抗性或后抗性癌症的识别，判断和治疗 Download PDF

Info

Publication number
CN102844664A
CN102844664A CN2011800058134A CN201180005813A CN102844664A CN 102844664 A CN102844664 A CN 102844664A CN 2011800058134 A CN2011800058134 A CN 2011800058134A CN 201180005813 A CN201180005813 A CN 201180005813A CN 102844664 A CN102844664 A CN 102844664A
Authority
CN
China
Prior art keywords
alk
cancer
polypeptide
protein
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800058134A
Other languages
English (en)
Chinese (zh)
Inventor
马诺·真田广之
崔英李
苏达学
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jichi Medical University
Original Assignee
Jichi Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jichi Medical University filed Critical Jichi Medical University
Priority to CN201410061691.6A priority Critical patent/CN103937877B/zh
Publication of CN102844664A publication Critical patent/CN102844664A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800058134A 2010-02-04 2011-02-04 对alk抑制剂具有先抗性或后抗性癌症的识别，判断和治疗 Pending CN102844664A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410061691.6A CN103937877B (zh) 2010-02-04 2011-02-04 对alk抑制剂具有先抗性或后抗性癌症的识别，判断和治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33746510P 2010-02-04 2010-02-04
US61/337,465 2010-02-04
PCT/IB2011/000382 WO2011095894A2 (en) 2010-02-04 2011-02-04 Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410061691.6A Division CN103937877B (zh) 2010-02-04 2011-02-04 对alk抑制剂具有先抗性或后抗性癌症的识别，判断和治疗

Publications (1)

Publication Number Publication Date
CN102844664A true CN102844664A (zh) 2012-12-26

Family

ID=44355876

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800058134A Pending CN102844664A (zh) 2010-02-04 2011-02-04 对alk抑制剂具有先抗性或后抗性癌症的识别，判断和治疗
CN201410061691.6A Expired - Fee Related CN103937877B (zh) 2010-02-04 2011-02-04 对alk抑制剂具有先抗性或后抗性癌症的识别，判断和治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410061691.6A Expired - Fee Related CN103937877B (zh) 2010-02-04 2011-02-04 对alk抑制剂具有先抗性或后抗性癌症的识别，判断和治疗

Country Status (17)

Country Link
US (1) US9018230B2 (https=)
EP (1) EP2531858B1 (https=)
JP (1) JP5937017B2 (https=)
KR (1) KR101843967B1 (https=)
CN (2) CN102844664A (https=)
AR (1) AR080361A1 (https=)
AU (1) AU2011212165B2 (https=)
BR (1) BR112012019215A2 (https=)
CA (1) CA2786974C (https=)
ES (1) ES2660149T3 (https=)
MX (1) MX336498B (https=)
NZ (1) NZ601606A (https=)
RU (1) RU2589834C2 (https=)
SG (1) SG182766A1 (https=)
TW (1) TWI518325B (https=)
WO (1) WO2011095894A2 (https=)
ZA (1) ZA201205831B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109312406A (zh) * 2016-06-01 2019-02-05 豪夫迈·罗氏有限公司 预测肺癌患者中对alk抑制剂疗法的响应的间变性淋巴瘤激酶中的新型突变

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383793B2 (en) * 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
US20120101108A1 (en) * 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
JP6205216B2 (ja) * 2012-09-24 2017-09-27 アークレイ株式会社 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット
US9428812B2 (en) * 2014-04-28 2016-08-30 Insight Genetics, Inc. Kit comprising primers for amplifying ALK kinase domain nucleic acids
DK4074735T3 (da) * 2014-08-28 2025-07-14 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
KR101872624B1 (ko) * 2016-12-27 2018-06-28 (주) 바이오인프라생명과학 Alk 표적 치료제에 대한 폐암의 치료 반응성을 예측하는 방법
CN107828823A (zh) * 2017-09-29 2018-03-23 暨南大学 一种评价eml4‑alk抑制剂对肺癌治疗效果的方法
RU2717309C2 (ru) * 2018-08-01 2020-03-20 Общество с ограниченной ответственностью "ОНКОДИАГНОСТИКА АТЛАС" Способ определения микросателлитной нестабильности
BR112020026259A2 (pt) 2018-11-01 2021-07-27 Illumina, Inc. métodos e composições para detecção de variante de linhagem germinativa
CN115997008A (zh) 2020-04-22 2023-04-21 艾欧凡斯生物治疗公司 协调用于患者特异性免疫疗法的细胞的制造的系统和方法
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2024017352A1 (zh) * 2022-07-22 2024-01-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004343A2 (en) * 1999-07-09 2001-01-18 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
CN1918158A (zh) * 2004-02-14 2007-02-21 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101466721A (zh) * 2007-04-13 2009-06-24 细胞信号技术公司 在人实体瘤中的基因缺损和突变体alk激酶

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
ATE138106T1 (de) 1988-07-20 1996-06-15 David Segev Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2005589C (en) 1988-12-16 2001-02-06 Akzo Nobel Nv Self-sustained, sequence replication system
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
IE66597B1 (en) 1989-05-10 1996-01-24 Akzo Nv Method for the synthesis of ribonucleic acid (RNA)
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
JPH04501510A (ja) 1989-07-25 1992-03-19 セル　ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同性組換え
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
MA22668A1 (fr) 1990-07-10 1993-07-01 Smithkline Beecham Corp Procede de preparation d'oxamides .
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6277569B1 (en) 1990-09-20 2001-08-21 Vysis, Inc. Methods for multiple direct label probe detection of multiple chromosomes or regions thereof by in situ hybridization
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
EP0636186B1 (en) 1992-04-03 1998-11-25 The Perkin-Elmer Corporation Probe composition and method
FR2690691B1 (fr) 1992-04-29 1999-02-12 Bio Merieux Procede d'amplification d'arn necessitant une seule etape de manipulation.
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
CA2158642A1 (en) 1993-03-19 1994-09-29 Hubert Koster Dna sequencing by mass spectrometry via exonuclease degradation
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5571676A (en) 1995-06-07 1996-11-05 Ig Laboratories, Inc. Method for mismatch-directed in vitro DNA sequencing
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6261775B1 (en) 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma
PT2450437T (pt) * 2006-04-14 2017-08-25 Cell Signaling Technology Inc Defeitos de genes e cinase alk mutante em tumores sólidos humanos
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
KR20100135780A (ko) 2008-03-06 2010-12-27 제넨테크, 인크. Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
AU2010248782B2 (en) 2009-05-15 2015-06-11 Insight Genetics, Inc. Methods and compositions relating to fusions of ALK for diagnosing and treating cancer
US9031642B2 (en) 2013-02-21 2015-05-12 Medtronic, Inc. Methods for simultaneous cardiac substrate mapping using spatial correlation maps between neighboring unipolar electrograms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004343A2 (en) * 1999-07-09 2001-01-18 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
CN1918158A (zh) * 2004-02-14 2007-02-21 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101466721A (zh) * 2007-04-13 2009-06-24 细胞信号技术公司 在人实体瘤中的基因缺损和突变体alk激酶

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIHUI LU, ET AL.: "ALK mutants in the Kinase Domain Exhibit Altered Kinase Activity and Differential Sensitivity to Small Molecule ALK Inhibitors", 《BIOCHEMISTRY》, vol. 48, no. 16, 27 February 2009 (2009-02-27), pages 3600 - 3609, XP002656287, DOI: doi:10.1021/BI8020923 *
MANABU SODA, ET AL.: "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", 《NATURE》, vol. 448, no. 7153, 2 August 2007 (2007-08-02), pages 561 - 566, XP002464689, DOI: doi:10.1038/nature05945 *
YOUNG LIM CHOI, ET AL.: "Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer", 《CANCER RESEARCH》, vol. 68, no. 13, 1 July 2008 (2008-07-01), pages 4971 - 4976, XP055052552, DOI: doi:10.1158/0008-5472.CAN-07-6158 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109312406A (zh) * 2016-06-01 2019-02-05 豪夫迈·罗氏有限公司 预测肺癌患者中对alk抑制剂疗法的响应的间变性淋巴瘤激酶中的新型突变

Also Published As

Publication number Publication date
TWI518325B (zh) 2016-01-21
WO2011095894A2 (en) 2011-08-11
CA2786974A1 (en) 2011-08-11
HK1197922A1 (zh) 2015-02-27
TW201144807A (en) 2011-12-16
CN103937877B (zh) 2016-09-28
JP2013518579A (ja) 2013-05-23
KR101843967B1 (ko) 2018-03-30
WO2011095894A3 (en) 2012-03-01
CN103937877A (zh) 2014-07-23
ES2660149T3 (es) 2018-03-21
NZ601606A (en) 2014-06-27
MX336498B (es) 2016-01-21
EP2531858A4 (en) 2013-08-07
CA2786974C (en) 2018-05-01
MX2012008914A (es) 2012-11-30
RU2012133318A (ru) 2014-03-10
BR112012019215A2 (pt) 2016-10-25
US20130203810A1 (en) 2013-08-08
ZA201205831B (en) 2013-05-29
AU2011212165A1 (en) 2012-09-20
SG182766A1 (en) 2012-08-30
US9018230B2 (en) 2015-04-28
AU2011212165B2 (en) 2016-03-03
JP5937017B2 (ja) 2016-06-22
RU2589834C2 (ru) 2016-07-10
EP2531858B1 (en) 2018-01-10
EP2531858A2 (en) 2012-12-12
KR20120130329A (ko) 2012-11-30
AR080361A1 (es) 2012-04-04

Similar Documents

Publication Publication Date Title
CN103937877B (zh) 对alk抑制剂具有先抗性或后抗性癌症的识别，判断和治疗
US20030087266A1 (en) IGs as modifiers of the p53 pathway and methods of use
Bazenet et al. Phosphorylation of tyrosine 720 in the platelet-derived growth factor α receptor is required for binding of Grb2 and SHP-2 but not for activation of Ras or cell proliferation
JP2005501528A (ja) ｐ５３経路のモディファイヤーとしてのＧＦＡＴｓおよび使用方法
EP0759986B1 (en) Diagnostics for cancers expressing tyrosine phosphorylated crkl protein
US10429384B2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
WO2005089169A2 (en) Mptens as modifiers of the pten pathway and methods of use
US20030165497A1 (en) RRP sequences and knockout mice and uses thereof
US20030036078A1 (en) P5CRs as modifiers of the p53 pathway and methods of use
HK1197922B (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
JP2007525962A (ja) ＰＴＥＮ／ＩＧＦ経路のモディファイヤーとしてのＭＰＴＥＮｓおよび使用方法
US20070274914A1 (en) Mptens as Modifiers of the Pten/Igf Pathway and Methods of Use
JP2005520485A (ja) ＩＲＲＴＫおよびｐ２１経路のモディファイヤーとしてのＧＰＣｓおよび使用方法
JP2005516583A (ja) ｐ５３経路のモディファイヤーとしてのＡＤＳＬｓおよび使用方法
CA2494252A1 (en) Psmcs as modifiers of the rb pathway and methods of use
JP2007502119A (ja) βカテニン経路のモディファイヤーとしてのＵＰｓ及び使用方法
AU2002357329A1 (en) Modulating insulin receptor signaling through targeting facl
WO2003052068A2 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2007058933A2 (en) Melks as modifiers of the rho pathway and methods of use
CA2494240A1 (en) Maxs as modifiers of the axin pathway and methods of use
WO2004047761A2 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074671A2 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121226